Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Molecular Inhibitor of QSOX1 Suppresses Tumor Growth in vivo.

Fifield AL, Hanavan PD, Faigel DO, Sergienko E, Bobkov A, Meurice N, Petit JL, Polito A, Caulfield TR, Castle EP, Copland JA, Mukhopadhyay D, Pal K, Dutta SK, Luo H, Ho TH, Lake DF.

Mol Cancer Ther. 2019 Oct 1. pii: molcanther.0233.2019. doi: 10.1158/1535-7163.MCT-19-0233. [Epub ahead of print]

PMID:
31575656
2.

3D porous chitosan-alginate scaffold stiffness promotes differential responses in prostate cancer cell lines.

Xu K, Ganapathy K, Andl T, Wang Z, Copland JA, Chakrabarti R, Florczyk SJ.

Biomaterials. 2019 Oct;217:119311. doi: 10.1016/j.biomaterials.2019.119311. Epub 2019 Jun 28.

PMID:
31279100
3.

Aberrant lipid metabolism as a therapeutic target in liver cancer.

Pope ED 3rd, Kimbrough EO, Vemireddy LP, Surapaneni PK, Copland JA 3rd, Mody K.

Expert Opin Ther Targets. 2019 Jun;23(6):473-483. doi: 10.1080/14728222.2019.1615883. Epub 2019 May 10.

4.

Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies.

Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE.

Clin Cancer Res. 2019 May 15;25(10):3141-3151. doi: 10.1158/1078-0432.CCR-18-2953. Epub 2019 Feb 8.

PMID:
30737244
5.

Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions.

Bastea LI, Liou GY, Pandey V, Fleming AK, von Roemeling CA, Doeppler H, Li Z, Qiu Y, Edenfield B, Copland JA, Tun HW, Storz P.

Cancer Res. 2019 Apr 1;79(7):1535-1548. doi: 10.1158/0008-5472.CAN-18-1153. Epub 2019 Jan 29.

PMID:
30696657
6.

Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker development.

Schueler J, Klingner K, Bug D, Zoeller C, Maier A, Dong M, Willecke K, Peille AL, Steiner E, Landesfeind M, Copland JA, Siegers GM, Haferkamp A, Boehm K, Tsaur I, Schneider M.

Oncotarget. 2018 Jul 24;9(57):30946-30961. doi: 10.18632/oncotarget.25697. eCollection 2018 Jul 24.

7.

Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models.

Qiu Y, Li Z, Copland JA, Mehrling T, Tun HW.

Oncotarget. 2018 Jun 15;9(46):28155-28164. doi: 10.18632/oncotarget.25588. eCollection 2018 Jun 15.

8.

Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.

Marlow LA, Rohl SD, Miller JL, Knauf JA, Fagin JA, Ryder M, Milosevic D, Netzel BC, Grebe SK, Reddi HV, Smallridge RC, Copland JA.

J Clin Endocrinol Metab. 2018 Sep 1;103(9):3169-3182. doi: 10.1210/jc.2017-01845.

9.

DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.

Yu J, Qin B, Moyer AM, Nowsheen S, Liu T, Qin S, Zhuang Y, Liu D, Lu SW, Kalari KR, Visscher DW, Copland JA, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Lou Z, Suman VJ, Weinshilboum R, Boughey JC, Goetz MP, Wang L.

J Clin Invest. 2018 Jun 1;128(6):2376-2388. doi: 10.1172/JCI97924. Epub 2018 Apr 30.

10.

Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types.

Tailor PD, Kodeboyina SK, Bai S, Patel N, Sharma S, Ratnani A, Copland JA, She JX, Sharma A.

Oncotarget. 2018 Apr 3;9(25):17876-17888. doi: 10.18632/oncotarget.24947. eCollection 2018 Apr 3.

11.

Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF V600E -mutant melanoma.

Harris AL, Lee SE, Dawson LK, Marlow LA, Edenfield BH, Durham WF, Flotte TJ, Thompson M, Small DL, Synnott AJ, Markovic SN, Copland JA.

Oncotarget. 2017 Dec 23;9(13):10905-10919. doi: 10.18632/oncotarget.23649. eCollection 2018 Feb 16.

12.

Cytokeratin-8 in Anaplastic Thyroid Carcinoma: More Than a Simple Structural Cytoskeletal Protein.

Guo D, Xu Q, Pabla S, Koomen J, Biddinger P, Sharma A, Pabla S, Pacholczyk R, Chang CC, Friedrich K, Mohammed K, Smallridge RC, Copland JA, She JX, Weinberger PM.

Int J Mol Sci. 2018 Feb 14;19(2). pii: E577. doi: 10.3390/ijms19020577.

13.

Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy.

von Roemeling CA, Caulfield TR, Marlow L, Bok I, Wen J, Miller JL, Hughes R, Hazlehurst L, Pinkerton AB, Radisky DC, Tun HW, Kim YSB, Lane AL, Copland JA.

Oncotarget. 2017 Oct 6;9(1):3-20. doi: 10.18632/oncotarget.21545. eCollection 2018 Jan 2.

14.

Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.

Yu J, Qin B, Moyer AM, Sinnwell JP, Thompson KJ, Copland JA 3rd, Marlow LA, Miller JL, Yin P, Gao B, Minter-Dykhouse K, Tang X, McLaughlin SA, Moreno-Aspitia A, Schweitzer A, Lu Y, Hubbard J, Northfelt DW, Gray RJ, Hunt K, Conners AL, Suman VJ, Kalari KR, Ingle JN, Lou Z, Visscher DW, Weinshilboum R, Boughey JC, Goetz MP, Wang L.

Breast Cancer Res. 2017 Dec 6;19(1):130. doi: 10.1186/s13058-017-0920-8.

15.

Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model.

Qiu Y, Li Z, Pouzoulet F, Vishnu P, Copland JA 3rd, Knutson KL, Soussain C, Tun HW.

Br J Haematol. 2018 Nov;183(4):674-678. doi: 10.1111/bjh.15009. Epub 2017 Oct 26. No abstract available.

PMID:
29076134
16.

Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma.

Davila JI, Starr JS, Attia S, Wang C, Knudson RA, Necela BM, Sarangi V, Sun Z, Ren Y, Casler JD, Menke DM, Oliver GR, Joseph RW, Copland JA, Parker AS, Kocher JA, Thompson EA, Smallridge RC, Asmann YW.

Rare Tumors. 2017 Sep 15;9(2):6834. doi: 10.4081/rt.2017.6834. eCollection 2017 Jul 3.

17.

Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation.

Ma MKF, Lau EYT, Leung DHW, Lo J, Ho NPY, Cheng LKW, Ma S, Lin CH, Copland JA, Ding J, Lo RCL, Ng IOL, Lee TKW.

J Hepatol. 2017 Nov;67(5):979-990. doi: 10.1016/j.jhep.2017.06.015. Epub 2017 Jun 22.

PMID:
28647567
18.

Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.

Colon-Otero G, Weroha SJ, Foster NR, Haluska P, Hou X, Wahner-Hendrickson AE, Jatoi A, Block MS, Dinh TA, Robertson MW, Copland JA.

Gynecol Oncol. 2017 Jul;146(1):64-68. doi: 10.1016/j.ygyno.2017.04.020. Epub 2017 Apr 28.

PMID:
28461031
19.

Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.

Goetz MP, Kalari KR, Suman VJ, Moyer AM, Yu J, Visscher DW, Dockter TJ, Vedell PT, Sinnwell JP, Tang X, Thompson KJ, McLaughlin SA, Moreno-Aspitia A, Copland JA, Northfelt DW, Gray RJ, Hunt K, Conners A, Sicotte H, Eckel-Passow JE, Kocher JP, Ingle JN, Ellingson MS, McDonough M, Wieben ED, Weinshilboum R, Wang L, Boughey JC.

J Natl Cancer Inst. 2017 Jul 1;109(7). doi: 10.1093/jnci/djw306.

20.

Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.

Enomoto K, Zhu X, Park S, Zhao L, Zhu YJ, Willingham MC, Qi J, Copland JA, Meltzer P, Cheng SY.

J Clin Endocrinol Metab. 2017 Jul 1;102(7):2268-2280. doi: 10.1210/jc.2016-3771.

21.

Patient-derived tumor xenograft models for melanoma drug discovery.

Harris AL, Joseph RW, Copland JA.

Expert Opin Drug Discov. 2016 Sep;11(9):895-906. doi: 10.1080/17460441.2016.1216968. Review.

PMID:
27454070
22.

MYC Is a Crucial Mediator of TGFβ-Induced Invasion in Basal Breast Cancer.

Cichon MA, Moruzzi ME, Shqau TA, Miller E, Mehner C, Ethier SP, Copland JA, Radisky ES, Radisky DC.

Cancer Res. 2016 Jun 15;76(12):3520-30. doi: 10.1158/0008-5472.CAN-15-3465. Epub 2016 Apr 13.

23.

Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin.

Hall JC, Marlow LA, Mathias AC, Dawson LK, Durham WF, Meshaw KA, Mullin RJ, Synnott AJ, Small DL, Krishna M, von Hoff D, Schüler J, Hart SN, Couch FJ, Colon-Otero G, Copland JA.

J Transl Med. 2016 May 10;14(1):129. doi: 10.1186/s12967-016-0875-z.

24.

Proteotranscriptomic Analysis Reveals Stage Specific Changes in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma.

Neely BA, Wilkins CE, Marlow LA, Malyarenko D, Kim Y, Ignatchenko A, Sasinowska H, Sasinowski M, Nyalwidhe JO, Kislinger T, Copland JA, Drake RR.

PLoS One. 2016 Apr 29;11(4):e0154074. doi: 10.1371/journal.pone.0154074. eCollection 2016.

25.

Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma.

Yushi Q, Li Z, Von Roemeling CA, Doeppler H, Marlow LA, Kim BY, Radisky DC, Storz P, Copland JA, Tun HW.

Oncotarget. 2016 May 31;7(22):32156-71. doi: 10.18632/oncotarget.8537.

26.

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.

Mehner C, Oberg AL, Kalli KR, Nassar A, Hockla A, Pendlebury D, Cichon MA, Goergen KM, Maurer MJ, Goode EL, Keeney GL, Jatoi A, Sahin-Tóth M, Copland JA, Radisky DC, Radisky ES.

Oncotarget. 2015 Nov 3;6(34):35737-54. doi: 10.18632/oncotarget.5927.

27.

Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.

von Roemeling CA, Copland JA.

Expert Opin Ther Targets. 2016;20(2):159-66. doi: 10.1517/14728222.2016.1086341. Epub 2015 Sep 28. Review.

28.

Distinct E-cadherin-based complexes regulate cell behaviour through miRNA processing or Src and p120 catenin activity.

Kourtidis A, Ngok SP, Pulimeno P, Feathers RW, Carpio LR, Baker TR, Carr JM, Yan IK, Borges S, Perez EA, Storz P, Copland JA, Patel T, Thompson EA, Citi S, Anastasiadis PZ.

Nat Cell Biol. 2015 Sep;17(9):1145-57. doi: 10.1038/ncb3227. Epub 2015 Aug 24.

29.

RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.

Marlow LA, Bok I, Smallridge RC, Copland JA.

Endocr Relat Cancer. 2015 Oct;22(5):777-92. doi: 10.1530/ERC-14-0302. Epub 2015 Jul 23.

30.

Dynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironment.

Vlahopoulos SA, Cen O, Hengen N, Agan J, Moschovi M, Critselis E, Adamaki M, Bacopoulou F, Copland JA, Boldogh I, Karin M, Chrousos GP.

Cytokine Growth Factor Rev. 2015 Aug;26(4):389-403. doi: 10.1016/j.cytogfr.2015.06.001. Epub 2015 Jun 20. Review.

31.

Pro-Tumorigenic Phosphorylation of p120 Catenin in Renal and Breast Cancer.

Kourtidis A, Yanagisawa M, Huveldt D, Copland JA, Anastasiadis PZ.

PLoS One. 2015 Jun 11;10(6):e0129964. doi: 10.1371/journal.pone.0129964. eCollection 2015.

32.

Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.

Zhang L, Zhang Y, Mehta A, Boufraqech M, Davis S, Wang J, Tian Z, Yu Z, Boxer MB, Kiefer JA, Copland JA, Smallridge RC, Li Z, Shen M, Kebebew E.

Oncotarget. 2015 Apr 20;6(11):9073-85.

33.

Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.

von Roemeling CA, Marlow LA, Pinkerton AB, Crist A, Miller J, Tun HW, Smallridge RC, Copland JA.

J Clin Endocrinol Metab. 2015 May;100(5):E697-709. doi: 10.1210/jc.2014-2764. Epub 2015 Feb 12.

34.

High-grade endometrial stromal sarcoma as the initial presentation of an adult patient with Peutz-Jeghers Syndrome: a case report.

Noriega-Iriondo MF, Colon-Otero G, Kipp BR, Copland JA, Ferber MJ, Marlow LA, Roberts ME, Robertson MW, Dinh TA, Attia S, Geiger XJ, Riegert-Johnson DL.

Hered Cancer Clin Pract. 2015 Jan 23;13(1):6. doi: 10.1186/s13053-015-0027-0. eCollection 2015.

35.

MEN1 mutations in Hürthle cell (oncocytic) thyroid carcinoma.

Kasaian K, Chindris AM, Wiseman SM, Mungall KL, Zeng T, Tse K, Schein JE, Rivera M, Necela BM, Kachergus JM, Casler JD, Mungall AJ, Moore RA, Marra MA, Copland JA, Thompson EA, Smallridge RC, Jones SJ.

J Clin Endocrinol Metab. 2015 Apr;100(4):E611-5. doi: 10.1210/jc.2014-3622. Epub 2015 Jan 27.

36.

miR30a inhibits LOX expression and anaplastic thyroid cancer progression.

Boufraqech M, Nilubol N, Zhang L, Gara SK, Sadowski SM, Mehta A, He M, Davis S, Dreiling J, Copland JA, Smallridge RC, Quezado MM, Kebebew E.

Cancer Res. 2015 Jan 15;75(2):367-77. doi: 10.1158/0008-5472.CAN-14-2304. Epub 2014 Dec 8.

37.

S100A8 is a novel therapeutic target for anaplastic thyroid carcinoma.

Reeb AN, Li W, Sewell W, Marlow LA, Tun HW, Smallridge RC, Copland JA, Spradling K, Chernock R, Lin RY.

J Clin Endocrinol Metab. 2015 Feb;100(2):E232-42. doi: 10.1210/jc.2014-2988. Epub 2014 Nov 25.

38.

Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration.

Von Roemeling CA, Marlow LA, Radisky DC, Rohl A, Larsen HE, Wei J, Sasinowska H, Zhu H, Drake R, Sasinowski M, Tun HW, Copland JA.

Oncotarget. 2014 Jul 30;5(14):5320-34.

39.

Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4.

von Roemeling CA, Radisky DC, Marlow LA, Cooper SJ, Grebe SK, Anastasiadis PZ, Tun HW, Copland JA.

Cancer Res. 2014 Sep 1;74(17):4796-810. doi: 10.1158/0008-5472.CAN-14-0210. Epub 2014 Jun 24.

40.

RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.

Smallridge RC, Chindris AM, Asmann YW, Casler JD, Serie DJ, Reddi HV, Cradic KW, Rivera M, Grebe SK, Necela BM, Eberhardt NL, Carr JM, McIver B, Copland JA, Thompson EA.

J Clin Endocrinol Metab. 2014 Feb;99(2):E338-47. doi: 10.1210/jc.2013-2792. Epub 2013 Dec 2.

41.

The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.

Becker MN, Wu KJ, Marlow LA, Kreinest PA, Vonroemeling CA, Copland JA, Williams CR.

Urol Oncol. 2014 Apr;32(3):317-26. doi: 10.1016/j.urolonc.2013.06.002. Epub 2013 Sep 17.

42.

Matrix assisted laser desorption ionization imaging mass spectrometry workflow for spatial profiling analysis of N-linked glycan expression in tissues.

Powers TW, Jones EE, Betesh LR, Romano PR, Gao P, Copland JA, Mehta AS, Drake RR.

Anal Chem. 2013 Oct 15;85(20):9799-806. doi: 10.1021/ac402108x. Epub 2013 Oct 3.

43.

Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma.

von Roemeling CA, Marlow LA, Kennedy WP, Kennedy GT, Copland JA, Menefee ME.

Am J Cancer Res. 2013 Aug 14;3(4):390-401. eCollection 2013.

44.

Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.

Li Z, Qiu Y, Personett D, Huang P, Edenfield B, Katz J, Babusis D, Tang Y, Shirely MA, Moghaddam MF, Copland JA, Tun HW.

PLoS One. 2013 Aug 5;8(8):e71754. doi: 10.1371/journal.pone.0071754. Print 2013.

45.

Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.

von Roemeling CA, Marlow LA, Wei JJ, Cooper SJ, Caulfield TR, Wu K, Tan WW, Tun HW, Copland JA.

Clin Cancer Res. 2013 May 1;19(9):2368-80. doi: 10.1158/1078-0432.CCR-12-3249. Epub 2013 Apr 30.

46.

Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, Bible KC, Shah MH, Gramza AW, Klopper JP, Marlow LA, Heckman MG, Von Roemeling R.

J Clin Endocrinol Metab. 2013 Jun;98(6):2392-400. doi: 10.1210/jc.2013-1106. Epub 2013 Apr 15.

47.

Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.

Isham CR, Bossou AR, Negron V, Fisher KE, Kumar R, Marlow L, Lingle WL, Smallridge RC, Sherman EJ, Suman VJ, Copland JA, Bible KC.

Sci Transl Med. 2013 Jan 2;5(166):166ra3. doi: 10.1126/scitranslmed.3004358.

48.

PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Hockla A, Miller E, Salameh MA, Copland JA, Radisky DC, Radisky ES.

Mol Cancer Res. 2012 Dec;10(12):1555-66. doi: 10.1158/1541-7786.MCR-12-0314.

49.

Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.

Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C.

J Oncol Pract. 2012 May;8(3 Suppl):e1s-5s. doi: 10.1200/JOP.2011.000496.

50.

Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.

Cooper SJ, von Roemeling CA, Kang KH, Marlow LA, Grebe SK, Menefee ME, Tun HW, Colon-Otero G, Perez EA, Copland JA.

Mol Cancer Ther. 2012 Oct;11(10):2105-15. doi: 10.1158/1535-7163.MCT-11-0873. Epub 2012 Jul 23.

Supplemental Content

Loading ...
Support Center